Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Elixinol Wellness Ltd
ELLXF
Consumer Defensive
Household & Personal Products
Elixinol Wellness Limited is an Australia-based hemp company. The Company is engaged in marketing and selling hemp derived and other plant-based nutraceuticals, skincare and food products. In Australia, it operates a vertically integrated business, which produces, manufactures, and distributes a range of complementary products delivered across four verticals: human nutrition, human wellness...
, pet wellness and superfood ingredients. These products are sold under brands including Hemp Foods Australia, Mt Elephant and Field Day and are sold through grocery, wholesale, and e-commerce channels. In the Americas, it is engaged in marketing and selling quality Elixinol branded hemp and other plant-derived nutraceutical and skincare products based in Colorado, United States. In the United Kingdom, Japan, Brazil, Mexico and South Africa, branded hemp and other plant-derived products are available to consumers via exclusive distribution and/or trademark and know-how licensing agreements.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCPK:ELLXF)
New Post
View:
Posts & Comments
Threaded Posts
(55)
•••
JasleenDhaka
X
View Profile
View Bullboard History
Post by
JasleenDhaka
on Mar 13, 2023 5:33pm
New Analyst Report on Elixinol!
Elixinol Wellness Limited (ASX: EXL / OTC: ELLXF) is expanding CBD market with its diverse product offerings and extensive distribution network. While revenue fell in 2022, EXL's cost-cutting
...more
(1)
•••
Mike411Ontario
X
View Profile
View Bullboard History
Post by
Mike411Ontario
on Apr 02, 2019 12:21pm
When is Earnings?
Does anyone know the earnings date?
C.RVV Announces Type C Meeting Request Granted by FDA for Clinical Study
posted Apr 24, 2024 9:00am by
Revive Therapeutics Ltd.
-
|
Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA ...read more
(1)
•••
Mike411Ontario
X
View Profile
View Bullboard History
Post by
Mike411Ontario
on Mar 29, 2019 7:55pm
Elixinol Global Investors Deck
Investor update:March / April 2019 Link A$1.00 = $.70US
(0)
•••
kim32865
X
View Profile
View Bullboard History
Post by
kim32865
on Mar 20, 2019 3:48pm
Up 5% today
I'm shocked there's no one talking about ELLXF.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover a Green Resources Stock Scoring Record Quarterly Growth
Stage Set for Creation of a Leading Intermediate Gold Producer
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study